Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myriad Genetics reports robust Q4 growth and eyes market expansion

Myriad Genetics showcased strong revenue growth and strategic initiatives to drive profitability in Q4 2022.
The company's focus on customer engagement, product volumes, and market positioning reflects a commitment to growth and operational excellence.
Challenges in managing competition and optimizing operational efficiency are balanced by opportunities for revenue growth and market expansion.

Myriad Genetics reports strong Q1 earnings, eyes profitability in Q4

Myriad Genetics demonstrated robust performance in Q1, leveraging strategic partnerships and operational improvements to drive revenue growth and enhance testing volumes.
While facing challenges like billing issues and seasonality-related declines, the company remains focused on core products, profitability, and growth opportunities.
With a strong financial outlook, emphasis on innovation, and commercial initiatives, Myriad Genetics is well-positioned to capitalize on market opportunities and drive sustainable growth.

Myriad Genetics reports solid Q2 growth and strategic focus

Myriad Genetics showcased strong financial performance, operational efficiencies, and strategic focus on growth and profitability.
While facing challenges like milestone payment concerns and industry competition, the company's strengths in key segments and operational capabilities position them well.
Opportunities in product enhancements, channel expansions, and investor engagement pave the way for continued success and market leadership.

Myriad Genetics reports strong Q3 earnings and raises 2024 guidance

Myriad Genetics reported strong revenue growth and operational improvements, with a focus on key product lines and enhancing customer experience.
The company raised financial guidance for 2023 and introduced revenue guidance for 2024, showcasing confidence in achieving long-term growth targets.
Challenges include regulatory changes, market penetration, and maintaining profitability amidst competitive dynamics, while opportunities lie in sustained growth and revenue optimization.
Overall, Myriad Genetics demonstrated resilience and strategic focus in driving growth, improving margins, and navigating market challenges effectively.

Myriad Genetics reports strong Q4 performance and eyes market expansion

Myriad Genetics delivered a strong Q4 performance with a focus on growth, strategic investments, and operational improvements. The company faces challenges in pricing and reimbursement but sees opportunities in market expansion and new product launches. Overall, Myriad Genetics is optimistic about its future prospects and market positioning.

Myriad Genetics reports robust Q1 performance and eyes growth opportunities

Myriad Genetics delivered a strong quarter with revenue growth and positive EBITDA, focusing on strategic areas like oncology and women's health. The company is optimistic about exceeding guidance but remains cautious. Analysts raised inquiries about various segments and operational decisions, with the company emphasizing profitable growth and maintaining margins.

Myriad Genetics reports strong Q2 performance and raises revenue targets

Myriad Genetics delivered a robust Q2 performance with revenue growth, positive earnings, and strategic wins in payer coverage, setting the stage for continued growth.
The company's focus on efficiency, customer satisfaction, and profitable growth positions it well for future success amidst market challenges and opportunities.
With raised revenue targets, expanded market acceptance, and operational excellence, Myriad Genetics demonstrates resilience and adaptability in a dynamic healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nestle SA

Cimarex Energy

Alliance Data Systems

CBRE Group

Principal Financial Group

uniQure

The markets were lower across the board on Tuesday afternoon. All eyes on Wall Street are focused on the two-day Federal Reserve meeting, which began Tuesday, as many are waiting to hear how the narrative on inflation is portrayed.

Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls

SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company's transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021.

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Why Is Myriad (MYGN) Down 11.5% Since Last Earnings Report?

Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.

Myriad Genetics (MYGN) Sells myPath to Focus on Core Units

SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

FRESNO, Calif., May 27, 2021 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, now offers pharmacogenomics testing for patients suffering from depression or anxiety.

IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA. Q2 Solutions provides comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. Myriad RBM, which specializes in contract research services for the pharmaceutical industry, will be added to the overall Q2 Solutions menu and offerings.

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

New President Brings Proven Track Record in Women's Health; Direct to Physician and Direct to Patient Commercial Expertise New President Brings Proven Track Record in Women's Health; Direct to Physician and Direct to Patient Commercial Expertise

Myriad Genetics Appoints Melissa Gonzales to Lead Women's Health Business

Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing

Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.

Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property (IP), including the Vectra® test, from Myriad Autoimmune's business unit to Labcorp (NYSE: LH) for $150 million in cash. Labcorp is a leading global life sciences company and one of the nation's largest laboratory service providers.

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune's Vectra Testing Business to Labcorp

Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine

Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day

New poll shows 83% of people with depression agree life would be easier if others could understand their depression New poll shows 83% of people with depression agree life would be easier if others could understand their depression

Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment

SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will release its financial results for the quarter ended March 31, 2021 at 4:05 pm EDT on May 3, 2021. The company will not be hosting a quarterly earnings call given it will be holding an Investor Day event the morning of May 4, 2021 at 11:00 am EDT. The link to the Investor Day event and registration will be under the investor relations section of our corporate website.

Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021

SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has signed a definitive agreement to sell the Myriad myPath Melanoma, LLC, Laboratory, which is the laboratory that offers the myPath Melanoma test, to Castle Biosciences for $32.5 million in cash. Castle Biosciences is a specialty laboratory focused on advanced diagnostics for dermatologic cancers.

Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Becton, Dickinson and Co.

Hologic

Let's take a look at the three women healthcare MedTech stocks performing well lately.

3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19

Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.

Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement

SALT LAKE CITY, March 29, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer. In this role, he will be responsible for accelerating growth initiatives and building commercial capabilities, and digital platforms to better serve patients and healthcare providers, while driving increased market demand for the company's portfolio of existing and new products and services.

Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders

Why Is Myriad (MYGN) Down 6.5% Since Last Earnings Report?

Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who May Benefit from First-Line Lynparza® Maintenance Treatment Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who May Benefit from First-Line Lynparza® Maintenance Treatment

Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan

NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that the Shareholder Class Action Against Myriad Genetics, Inc. (NASDAQ: MYGN) has survived the motions to dismiss in the pending securities class action and may face damages. Long-term investors are encouraged to contact the firm. According to the securities class action complaint, throughout the Class Period defendants made materially false and misleading statements regar

MYRIAD GENETICS ALERT: Bragar Eagel & Squire, P.C. Announces the Shareholder Class Action Against Myriad Genetics, Inc. Survives Motion to Dismiss and Encourages Long-term Investors to Contact the Firm

Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.

Myriad Genetics (MYGN) Collaborates to Advance Oncology Care

Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care

News for Myriad Genetics Stock (MYGN)